Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-07-25 4:18 pm Purchase | 2023-05-25 | 13G | Icosavax, Inc. ICVX | TCG Crossover GP I, LLC | 3,703,704 7.500% | 3,703,704 (New Position) | Filing History |
| 2023-07-25 4:17 pm Purchase | 2023-07-17 | 13G | Savara Inc. SVRA | TCG Crossover GP I, LLC | 10,000,000 7.400% | 10,000,000 (New Position) | Filing History |
| 2023-02-14 2:23 pm Purchase | 2022-12-31 | 13G | Cogent Biosciences, Inc. COGT | TCG Crossover GP I, LLC | 3,631,042 5.200% | 3,631,042 (New Position) | Filing History |
| 2023-02-14 2:23 pm Purchase | 2022-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY | TCG Crossover GP I, LLC | 5,905,400 6.200% | 5,905,400 (New Position) | Filing History |
| 2023-02-14 2:23 pm Purchase | 2022-12-31 | 13G | Silence Therapeutics plc SLN | TCG Crossover GP I, LLC | 6,314,625 5.900% | 6,314,625 (New Position) | Filing History |
| 2023-02-14 2:23 pm Purchase | 2022-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | TCG Crossover GP I, LLC | 983,610 2.400% | 983,610 (New Position) | Filing History |
| 2023-01-09 4:19 pm Purchase | 2022-12-28 | 13D | KalVista Pharmaceuticals, Inc. KALV | TCG Crossover GP I, LLC | 3,408,081 9.900% | 3,408,081 (New Position) | Filing History |